ABSTRACT
Background Immune protection against SARS-CoV-2 can be induced by natural infection or vaccination or both. The interaction between vaccine-induced immunity and naturally acquired immunity at the population level has been understudied.
Methods We used regression models to evaluate whether the impact of COVID-19 vaccines differed across states with different levels of naturally acquired immunity from March 2021 to April 2022 in the United States. Analysis was conducted for three evaluation periods separately (Alpha, Delta, and Omicron waves). As a proxy of the proportion of the population with naturally acquired immunity, we used either the reported seroprevalence or the estimated proportion of the population ever infected in each state.
Results COVID-19 mortality decreased as the coverage of ≥1 dose increased among people ≥65 years of age, and this effect did not vary by seroprevalence or the proportion of the total population ever infected. Seroprevalence and the proportion ever infected were not associated with COVID-19 mortality, after controlling for vaccine coverage. These findings were consistent in all evaluation periods.
Conclusions COVID-19 vaccination was associated with a sustained reduction in mortality at the state level during the Alpha, Delta, and Omicron periods. The effect did not vary by naturally acquired immunity.
Competing Interest Statement
B.L. serves as a consultant to Epidemiological Research and Methods, LLC.
Funding Statement
Research reported in this publication was supported by Emory University, the MP3 Initiative and WHSC COVID-19 Urgent Research Engagement (CURE) Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of Emory University, the MP3 Initiative and WHSC COVID-19 Urgent Research Engagement (CURE) Center.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at the U.S. Centers for Disease Control and Prevention (CDC) websites.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest B.L. serves as a consultant to Epidemiological Research and Methods, LLC.
Funding statement Research reported in this publication was supported by Emory University, the MP3 Initiative and WHSC COVID-19 Urgent Research Engagement (CURE) Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of Emory University, the MP3 Initiative and WHSC COVID-19 Urgent Research Engagement (CURE) Center.
Data Availability
All data used in this study are publicly available online at the CDC websites cited in the manuscript.
